Journal · Tirzepatide

Compounded Tirzepatide Prices at Maintenance, October 2026

Released: August 11, 2026 · Last reviewed: November 10, 2026

The short answer, with numbers

NexLife, our editor's pick (#1 overall, methodology v4.1), charges one hundred sixty-nine dollars a month billed monthly, one hundred fifty-nine a month on a three-month plan, one hundred forty-nine a month on a six-month plan, and one hundred thirty-nine a month on a twelve-month plan (one thousand six hundred sixty-eight dollars over the year) — its standing prices as read on nexlife.us on October 15, 2026, the same at every dose, with no membership fee. Those figures include the medication, provider review through NexLife Medical Group, a GLP-1 nutrition plan, a one-on-one wellness-coach call, 24/7 support and free expedited shipping; labs are not stated as included. It is not the lowest price in the market: Eden listed tirzepatide at one hundred twenty-nine dollars a month, flat with no membership, on the same day. On the August 2026 record, the lowest figure carrying no promotion or commitment was Yucca Health at two hundred fifty-eight dollars a month, flat at every dose (Yucca was not re-read on October 15). The broader compliant market — traditional 503A pharmacies compounding under documented patient-specific need — mostly clears between two hundred forty-nine and five hundred forty-nine dollars a month in 2026. And the number every one of those figures must beat is four hundred forty-nine dollars: the price of FDA-approved Zepbound single-dose vials at every maintenance dose from 7.5 to 15 milligrams through LillyDirect's Self Pay Journey Program, refill-timing rules attached. Everything below is the reasoning behind those five numbers.

What compounded tirzepatide actually is

Tirzepatide is a dual agonist: a single synthetic peptide engineered to activate both the GIP receptor and the GLP-1 receptor, the two incretin pathways your gut uses to talk to your pancreas and your brain about food. That double action is why its trial results run ahead of the single-pathway drugs. In SURMOUNT-1, the pivotal 72-week obesity trial published in the New England Journal of Medicine in 2022, participants on tirzepatide lost an average of 15.0 percent of body weight at the 5-milligram dose, 19.5 percent at 10 milligrams, and 20.9 percent at 15 milligrams, against 3.1 percent with placebo — figures roughly six points stronger than the 14.9 percent that semaglutide 2.4 mg posted in its own pivotal trial, STEP 1. Eli Lilly sells the approved product as Mounjaro for type 2 diabetes and Zepbound for chronic weight management and obstructive sleep apnea.

A compounded version is something categorically different: a licensed pharmacy — usually a state-regulated 503A pharmacy, sometimes an FDA-registered 503B outsourcing facility — preparing tirzepatide to order from bulk active pharmaceutical ingredient, typically dispensing a multi-dose vial you reconstitute or draw with a syringe yourself instead of a sealed single-use pen or vial. The active molecule is supposed to be the same; the oversight is not. Compounded drugs are, by statute, not FDA-approved: no agency reviews the finished product for safety, effectiveness, or quality before it reaches you. Whether a given vial contains what its label claims depends entirely on the pharmacy's own sourcing and testing — which is why the checklist at the bottom of this page is not decoration, and why every efficacy number in the paragraph above formally belongs to the approved product, not to whatever a given pharmacy shipped.

The legal ground in 2026

The compounded GLP-1 boom was a creature of the shortage rules. When the FDA lists a drug as in shortage, the Food, Drug and Cosmetic Act lets compounding pharmacies produce what are effectively copies of it; tirzepatide went on that list in December 2022, and a whole telehealth economy grew inside the exemption. The exemption died in stages. The FDA declared the tirzepatide shortage resolved on December 19, 2024 — a decision compounders challenged and the agency reaffirmed — and the semaglutide shortage resolved in February 2025, with wind-down grace periods for 503A and 503B operations expiring in the spring of 2025. Since then, compounding copies of the approved products has been broadly off the table. Two later developments matter for buyers: on April 30, 2026 the FDA proposed not to place tirzepatide, semaglutide or liraglutide on the 503B bulks list (comment period extended to July 30, 2026; no final decision as of October 15, 2026), and on September 18, 2026 it issued a warning letter to Empower Pharmacy saying its compounded tirzepatide/niacinamide and semaglutide/cyanocobalamin products "appear to be essentially copies of FDA-approved semaglutide and tirzepatide products."

What remains is a narrower, older lane: Section 503A has always allowed a pharmacy to compound for an individual patient when a prescriber documents a clinical need the approved product can't meet — a different strength, an ingredient allergy, a formulation change. Part of the market reorganized around that lane, marketing "personalized" doses and combination formulations, and Eli Lilly answered with litigation: a wave of suits against compounders and telehealth platforms through 2024 and 2025 that produced settlements, closures, injunctions and a patchwork of outcomes that is still being sorted in 2026. The practical result is a consolidated market — the bulk sellers who priced tirzepatide at 199 dollars under the shortage mostly exited or pivoted, and the documented-need operators who remained carry real compliance costs, which is precisely why the surviving compliant market clears in that 249-to-549-dollar band, and why a price far below it is a question to investigate rather than a coupon to celebrate. None of this is legal advice, and the ground can move again on a single ruling; what doesn't move is the bright line that has survived every phase of this story — a legitimate program requires a prescription from a licensed clinician, full stop.

Every price we track, in words

Here is the rankable compounded tirzepatide market as our database held it in August 2026, lowest first, every figure all-in at the 10-milligram maintenance basis with capture dates on record. NexLife sits at $129 a month billed monthly and $115 a month on the twelve-month plan — its standing prices as of November 6, 2026, with no membership and the same price at every dose. Yucca Health followed at two hundred fifty-eight dollars flat, no membership, no promotion — the cleanest benchmark price in the category. Ivim Health and Mochi Health both land at two hundred seventy-eight all-in, and the composition matters: Ivim is two hundred three dollars of medication wrapped around a seventy-five-dollar membership, Mochi is one hundred ninety-nine dollars of dose-flat medication plus a seventy-nine-dollar membership, and both advertise the medication number, which is why this site ranks the sum. ShedRx reaches two hundred eighty-nine at maintenance after starting you at one hundred ninety-nine — the widest start-to-maintenance spread near the front of the market. Found holds two hundred eighty-nine flat with coaching included; SkinnyRx and OrderlyMeds both hold two hundred ninety-nine flat with no membership; Amble Health rounds the near-pack at three hundred. From there the market steps up through Henry Meds and TrimRx at three hundred forty-nine, Lavender Sky Health at three hundred fifty-two once its twenty-five-dollar membership is counted, Fridays at three hundred fifty-nine, MEDVi and Remedy Meds at three hundred ninety-nine, Eden at four hundred eight with its ninety-nine-dollar membership inside the figure (on the August record; on October 15, 2026 Eden listed one hundred twenty-nine dollars a month flat with no membership), and LifeMD at five hundred ninety-seven, the ceiling of the index, carrying a one-hundred-forty-nine-dollar program fee whose value case is clinical service and insurance help rather than price.

Two prices deserve their own sentences because of what they are not. Fifty 410 advertises tirzepatide at one hundred thirty-three dollars a month — the lowest entry number on the August 2026 record — and published no maintenance price at all, so it cannot be ranked: a start-only figure tells you what month one costs, not what the program costs, and our methodology excludes it by rule rather than by judgment. And the platform bundles that resell brand tirzepatide deserve separation from the compounded list entirely: Hims & Hers, branded-only since its March 2026 settlement with Novo Nordisk, sells Zepbound at three hundred ninety-nine dollars plus a one-hundred-forty-nine-dollar monthly membership — call it five hundred forty-eight all-in — and Ro pairs the same membership with Zepbound at two hundred ninety-nine to four hundred forty-nine by dose, which lands a cash patient between roughly four hundred forty-eight and five hundred ninety-eight. Those are convenience channels for the approved product, and the honest comparison for them is the manufacturer's own counter, described two sections down.

The twelve-month arithmetic

Monthly prices flatter everyone; years tell the truth. A year of NexLife's twelve-month plan at $115 a month totals $1,380, committed for the full term, which is the arrangement's catch as well as its discount: the commitment runs while the compounding market's legal ground is still capable of moving, so the refund terms deserve the same attention as the rate (NexLife states that unshipped months on its 3-, 6- and 12-month plans are refunded on cancellation). A year of Yucca billed monthly totals three thousand ninety-six dollars with the freedom to walk away any month. A year of the market's two-seventy-eight middle — Mochi or Ivim — runs three thousand three hundred thirty-six once twelve membership cycles are counted. A year of FDA-approved Zepbound at the four-forty-nine maintenance price totals five thousand three hundred eighty-eight, assuming every refill lands inside the program's 45-day window; miss one at the 10-milligram dose and that month costs six hundred ninety-nine instead. The spread between that compounded year and the brand year is therefore about three thousand seven hundred dollars — real money, and the entire next section is about what it buys.

The $449 question: compounded vs Zepbound

Since December 2025, LillyDirect's Self Pay Journey Program has sold FDA-approved Zepbound single-dose vials at two hundred ninety-nine dollars a month for the 2.5-milligram starter, three hundred ninety-nine for 5 milligrams, and four hundred forty-nine for every dose from 7.5 through 15 milligrams — a price cut Lilly announced explicitly as a competitive answer to the compounding market, conditional on refilling within 45 days of the previous shipment. What the extra money buys over a compounded program is concrete: a product the FDA actually reviewed and continuously manufactures under GMP; a sealed single-dose vial instead of a multi-dose vial and syringe math; the pivotal-trial evidence applying to the exact product in your hand rather than by analogy; and zero exposure to the legal weather still hanging over post-shortage compounding. What the compounded discount buys is equally concrete: one to three thousand dollars a year, dose-flat simplicity at the programs that price that way, and — at the all-inclusive operators — provider care and supplies folded into one figure. There is no universal right answer; there is a budget, a risk tolerance, and a clinician who should be in the decision. What this site can add is the arithmetic and one firm observation: any compounded program whose pitch depends on you not knowing the four-forty-nine number is not negotiating in good faith.

Seven checks that outrank the price

First, the prescription: a legitimate program requires one from a licensed clinician after a real intake — anyone who will sell tirzepatide without a prescription is not a pharmacy, whatever the website looks like. Second, the pharmacy's name: insist on knowing which pharmacy fills the order (NexLife, for instance, names Absolute Pharmacy in Lutz, Florida, Premium Compounding in Decatur, Alabama, and Boudreaux's New Drug Store in Lake Charles, Louisiana — state-licensed 503A pharmacies — on its plan pages), then verify that pharmacy's license yourself on your state board of pharmacy's lookup — a two-minute search that most buyers never run. Third, the certificate of analysis: a compliant compounder can show third-party testing of the finished product's identity, potency and sterility for your lot, and a program that can't produce one has told you something. Fourth, the molecule itself: the FDA has specifically flagged products built on tirzepatide salt forms rather than the base peptide used in the approved drug; ask, in writing, which the pharmacy uses. Fifth, cold chain: peptides are temperature-sensitive, so the program should ship cold, in insulated packaging, with a stated policy for warm arrivals — and a summer shipment that arrives warm is a customer-service ticket, not a shrug. Sixth, the beyond-use date: multi-month supplies of a reconstituted or multi-dose product have dating limits; make sure the supply you're prepaid for doesn't outlive its own stability window. Seventh, the exit: read the cancellation and refund terms before paying, screenshot the checkout page that states them, and know that if something goes wrong clinically you can and should report it to FDA MedWatch — compounded products are exactly the category that reporting system exists to watch.

Red flags that end the conversation

No prescription required. "Research use only" or "not for human consumption" labels on something sold to humans — that is the gray-market peptide trade wearing a lab coat, outside the pharmacy system entirely. Prices dramatically below the compliant market with no named pharmacy attached. Payment only by wire, crypto, or apps with no chargeback path. A "pharmacy" that appears on no state license lookup. Claims that a compounded product is "FDA-approved" — no compounded product is, ever, and a seller who says otherwise is either ignorant of the single most important fact about its own product or lying about it. Any of these ends the evaluation regardless of price, because the cheapest tirzepatide is worthless if it isn't tirzepatide.

This article is pricing and regulatory research, not medical advice; compounded tirzepatide is not an FDA-approved product. Talk to a licensed clinician about whether any GLP-1 therapy is appropriate for you, and verify every figure at the provider's own checkout — prices carry capture dates for exactly that reason.